At the end of the year, against the backdrop of a shrinkage of global M&A deals22, healthcare took the lead in recovery, with a deal value increase of 9% to US$410 billion, making it the second largest industry in terms of global M&A deal value. A-share biotechnology led the overall gains of the Shanghai Composite Index by 17, and became a "money-making" sector in the second half of the year.
MNC is a big deal. In 2023, there will be a total of 25 transactions of more than US$1 billion in the biomedical field, with an average acquisition premium of 17 times, of which Pfizer's $43 billion acquisition of Seagen became the "champion" of this year's transaction, "Bangyan" is BMS to win Karuna with 140, and "Tanhua" belongs to Merk to spend $10.8 billion to acquire Prometheus. At the same time, the MNC is still busy "picking up leaks", and AbbVie spent a total of $18.8 billion in December to buy ADC and CNS first-class assetsDanaher and Thermo Fisher Scientific acquire leading companies in antibody and proteomics at a low market valuationAstraZeneca took the lead in testing the waters in China with the US$1.2 billion acquisition of Danxi Biotech.
Local pharmaceutical companies are "** double heavens". In 2023, the M&A transactions of local pharmaceutical companies will be lackluster, and the pharmaceutical IPO market will experience a "cliff-like" decline, with the number of IPOs in the A-share biopharmaceutical industry falling from 49 last year to 21 this year, and the amount of financing falling by 70.0% from 74.9 billion yuan last year15% to 2235.6 billion yuan. As of November 2023, Chinese pharmaceutical companies have had a total of 40 overseas transactions, with a cumulative value of more than US$30 billion[1].
Pharmaceutical mergers and acquisitions in 2023, which took the lead in recovery, were thunderous!
In 2024, the year of great changes is brewing, the waves of the four seas are high, and the future will disappear!
Produced by Gao Sheng Academy.
Note 1: This article cites the articles of "Wind", "Oriental Fortune Choice Data Terminal", "Self-*** Biopharmaceutical Era", and "Claudisrian Medicine".